桑名 正隆 くわな まさたか 先生

来歴等

略歴

1988年　慶應義塾大学医学部卒業
1992年　慶應義塾大学大学院医学研究科博士課程修了
1993年　ピッツバーグ大学リウマチ内科ポストドクトラルフェロー
2000年　慶應義塾大学医学部先端医科学研究所専任講師
2006年　慶應義塾大学医学部内科(血液感染リウマチ)助教授
2007年　慶應義塾大学医学部内科(リウマチ)准教授
2014年　日本医科大学大学院医学研究科アレルギー膠原病内科学分野 大学院教授
　　　　 日本医科大学付属病院リウマチ・膠原病内科 部長

論文

主な論文業績(計292の査読英文論文から抜粋 *corresponding author)
1. *Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J. Clin. Invest. 1993; 91(4): 1399-1404.
2. *Kuwana M, Kaburaki J, Okano Y, Inoko H, Tsuji K. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J. Clin. Invest. 1993; 92 (3): 1296-1301.
3. *Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994; 37(1): 75-83.
4. *Kuwana M, Medsger TA Jr, Wright TM. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J. Clin. Invest. 1995; 96(1): 586-596.
5. *Kuwana M, Medsger TA Jr, Wright TM. Highly restricted TCR  usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J. Immunol. 1997; 158(1): 485-491.
6. Arai T, Yoshida K, Kaburaki J, Inoko H, Ikeda Y, Kawakami Y, *Kuwana M. Autoreactive CD4+ T cell clones to 2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood. 2001; 98(6): 1889-1896.
7. *Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004; 364(9434): 603-610.
8. *Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005; 52(8): 2425-2432.
9. *Kuwana M, Okazaki Y, Kodama H, Satoh T, Kawakami Y, Ikeda Y. Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells. 2006; 24(12): 2733-2743.
10. Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, *Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to 2-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007; 110(13): 4312–4318.
11. Takahashi H, Amagai M, Nishikawa T, Fujii Y, Kawakami Y, *Kuwana M. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T-cell clones using murine pemphigus vulgaris. J. Immunol. 2008; 181(2): 1526-1535.
12. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, Ikeda Y, *Kuwana M. Helicobacter pylori eradication shifts monocytes’ Fc receptor balance toward inhibitory FcRIIB in immune thrombocytopenic purpura. J. Clin. Invest. 2008;118(8): 2939-2949.
13. Kawai M, Masuda A, *Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum. 2008; 58(11): 3562-3573.
14. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, *Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60(7): 2193-2200.
15. Hoshino K, Satoh T, Kawaguchi Y, *Kuwana M. Association of Hepatocyte Growth Factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum. 2011; 63(8): 2465-2472.
16. *Kuwana M, Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann. Rheum. Dis. 2012; 71(4): 617-620.
17. *Kuwana M, Okazaki Y. Impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheumatol. 2014; 66(5): 1300-1305.
18. Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, *Kuwana M. Elevated pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol. 2015; 67(2): 498-507.
19. Gono T, Kuwana M, et al. Risk stratification modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease: JAMI risk score. Arthritis Rheumatol. In press
20. Highland KB, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: subgroup analysis of the SENSCIS trial. Lancet Respir. Med. In press.
21. Khanna D, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30318-0 [Epub ahead of print]
22. Nagaraja V, Kuwana M, et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol. 2020; 72(7): 1049-1058.
23. Kuwana M, et al. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: a post hoc analysis. Ann. Rheum. Dis. 2020; 79(5): 626-634.
24. Yamasaki Y, Kuwana M. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Rev. Clin. Immunol. 2020; 16(6); 547-559.
25. Khanna D, Kuwana M, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomized, double-blind, placebo-controlled multicenter trial. Ann. Rheum. Dis. 2020; 79(5): 618-625.
26. Gono T, Kuwana M. Current understanding and recent advances in dermatomyositis-related autoantibodies. Expert Rev. Clin. Immunol. 2020; 16(1): 79-89.
27. Volkmann ER, Kuwana M,et al. Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019; 71(12): 2059-2067.
28. Distler O, Kuwana M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 2019; 380(26): 2518-2528.

その他

• 【受賞】1995年　American College of Rheumatology Senior Rheumatology Scholarship Award

• 【受賞】2004年　日本結合組織学会大高賞

• 【受賞】2007年　アボットジャパン・リウマチ性疾患臨床医学賞

• 【受賞】2009年　慶応義塾大学知的資産センター賞

• 【受賞】2017年　日本リウマチ学会賞